World

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

 March 02, 2026 | News

SystImmune And Bristol Myers Squibb Report Dual PFS And OS Success For Iza Bren In Phase III TNBC Trial

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”...

 March 02, 2026 | News

Brainlab And Precision NeuroMed Partner To Advance AI Enabled Convection Enhanced Delivery Platform

Brainlab SE (Brainlab), a digital medical technology company automating and optimizing clinical workflows using artificial intelligence and sophistica...

 February 27, 2026 | News

Gilead Reports Positive Phase 3 Data For Investigational Bictegravir And Lenacapavir Single Tablet Regimen

– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier ...

 February 27, 2026 | News

Suvoda Introduces Split Budget Capability To Streamline Global Clinical Trial Site Agreements

Suvoda, a clinical trial technology company announced new split budget functionality within its Budgeting & Benchmarking solution, expanding how sponso...

 February 27, 2026 | News

Japan Approves Alpha DaRT To Expand Treatment Options In Head And Neck Cancer

Offering a New Option for Head and Neck Cancer Treatment HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor tr...

 February 27, 2026 | News

SteinCares And Shilpa Biologicals Sign Strategic Licensing Agreement To Commercialise Biosimilar Across Latin America

New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform Collaborati...

 February 26, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

 February 25, 2026 | News

Etherna And Almirall Advance LAD116 mRNA LNP Therapy Into IND Enabling Studies For Non Melanoma Skin Cancer

 etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...

 February 25, 2026 | News

Singular Genomics Commercially Launches G4X to Scale Spatial Multiomics for Precision Medicine

 Singular Genomics, a company delivering high-throughput spatial technologies to advance precision medicine, announced the commercial launch...

 February 24, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

–  Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

 February 24, 2026 | News

Lunai Bioworks Secures Foundational U.S. Patent to Advance AI-Driven Precision Medicine

Foundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene Mapping Lunai Bioworks, Inc. (NASDAQ: ...

 February 24, 2026 | News

Catalent And S Biomedics Partner To Advance Stem Cell Therapy For Parkinsons Disease

Catalent and S.Biomedics announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripot...

 February 23, 2026 | News

Takeda Reports Positive Phase 3 KEPLER Data For ENTYVIO In Pediatric Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...

 February 23, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close